AZD4117

Developed for: influenza
Investigated by: AstraZeneca · Biomedical Advanced Research and Development Authority · Joint Program Executive Office (JPEO) Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB)

today NCT07128615 · Ph 1/2

2026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/2	NCT07128615	Sep 2025 → Jan 2026 overdue	influenza	AstraZeneca	Active not recruiting	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	AZD4117	ClinicalTrials.gov intervention name — accepted as the source's own label NCT07128615 ↗
Route	Intramuscular	“Intramuscular (IM) injection” NCT07128615 ↗